Systematic Evaluation of Antiviral Medication in Schizophrenia

The main objective of the study is to evaluate the efficacy of add-on treatment of
Valacyclovir (VAV), an antiviral medication, in the treatment of early course
schizophrenia/schizoaffective disorder patients. Our main hypothesis is that the VAV add-on
treatment will improve positive, negative and cognitive symptoms in herpes simplex virus
(HSV) positive schizophrenia or schizoaffective disorder patients. We hypothesize that the
grey matter reductions in specific brain regions (such as prefrontal regions) will improve in
patients on VAV + antipsychotic compared to those on placebo + antipsychotic and the
improvements in positive, negative and cognitive symptoms will be correlated with the grey
matter changes.

Inclusion Criteria:

- Both genders between the ages of 18-50 years

- Schizophrenia or schizoaffective disorder as defined in DSM-IV

- Duration of illness 10 years or less

- On a stable dose of an antipsychotic medication for at least a month

- Should score 4 or more on at least one of the subscales of PANSS

- Positive for HSV1

- Written informed consent

Exclusion Criteria:

- Substance abuse in the last month/dependence 6 months prior to the study

- History of, or current medical/neurological illnesses which affects CNS function e.g.,
epilepsy, head injury with prolonged loss of consciousness

- Pregnancy

- History of immune disorders, HIV infection or currently receiving immunosuppressants

- Subjects on regular antiviral therapy

- History of hypersensitivity to Valacyclovir

- Mental retardation as defined in DSM-IV